Lung Cancer Treatment in India
Get Lung Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Lung Cancer Treatment in UAE
Lung Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Lung cancer treatment encompasses a multidisciplinary spectrum of interventions — including anatomic resection, stereotactic body radiotherapy (SBRT), platinum-doublet chemotherapy, targeted molecular therapy (EGFR, ALK, ROS1 inhibitors), and immune checkpoint immunotherapy — tailored to histological subtype, stage, and genomic profile. Early-stage non-small cell lung cancer (NSCLC) achieves 5-year survival rates exceeding 70–90% with curative-intent surgery or SBRT, while advanced-stage disease managed with modern targeted agents or immunotherapy demonstrates objective response rates of 40–70% depending on biomarker status. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centres in India and JCI- and DHA-licensed cancer institutes in Dubai and Abu Dhabi, offering world-class multidisciplinary tumour boards, robotic-assisted thoracic surgery, and next-generation sequencing (NGS)-guided treatment — at a fraction of Western costs and with full end-to-end coordination.
Hospital Stay: 5–14 days (varies by modality: 5–7 days for VATS/robotic lobectomy; up to 14 days for open pneumonectomy or complex chemo-induction cases) • Total Stay in Country (Fit-to-Fly): 3–6 weeks (3 weeks post VATS/robotic resection or SBRT completion; 5–6 weeks post open thoracotomy or pneumonectomy; ongoing systemic therapy patients travel only after oncologist clearance and confirmed DVT prophylaxis plan) • Success Rate: 70–90% 5-year survival (Stage I NSCLC with curative resection or SBRT); 40–65% objective response rate (Stage III–IV with targeted therapy or immunotherapy)
What Is It?
Lung cancer is a malignancy arising from the bronchial epithelium or alveolar parenchyma and is broadly classified into non-small cell lung cancer (NSCLC — comprising adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma, accounting for ~85% of cases) and small cell lung cancer (SCLC, ~15% of cases). NSCLC staging follows the TNM 9th Edition system (IASLC 2024), with Stage I–II disease amenable to curative-intent surgery or definitive radiotherapy, Stage III disease managed with concurrent chemoradiotherapy ± consolidation immunotherapy (e.g., durvalumab per the PACIFIC trial), and Stage IV disease approached with systemic therapy guided by comprehensive biomarker profiling. SCLC is staged as limited-stage (LS-SCLC) or extensive-stage (ES-SCLC), with concurrent chemoradiation for LS-SCLC and platinum-etoposide plus atezolizumab or durvalumab for ES-SCLC.
Physiologically, lung cancer impairs gas exchange progressively as tumour burden obstructs airways, invades the pulmonary vasculature, or seeds the pleural space (malignant pleural effusion). Paraneoplastic syndromes — including hypercalcaemia (PTHrP secretion in squamous cell carcinoma), SIADH (SCLC), Cushing syndrome (ectopic ACTH), and Lambert-Eaton myasthenic syndrome — may predate or complicate the primary diagnosis. Metastatic spread to the brain, adrenal glands, bone, and liver is common, particularly in SCLC and EGFR-mutant adenocarcinoma.
The international standard of care mandates tissue diagnosis with histological subtyping, followed by comprehensive molecular profiling via next-generation sequencing (NGS) panels — testing at minimum for EGFR mutations (exon 19 deletions, exon 21 L858R, exon 20 insertions), ALK and ROS1 gene rearrangements, KRAS G12C, BRAF V600E, MET exon 14 skipping, RET fusions, NTRK fusions, and PD-L1 expression (TPS and CPS scoring). Treatment decisions are made by a dedicated thoracic multidisciplinary tumour board (MDT) comprising thoracic surgery, medical oncology, radiation oncology, radiology, pulmonology, and palliative care — the precise model practised at GAF Healthcare's partner centres in India and the UAE.
Candidates
• ELIGIBLE PATIENTS:
• Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage seeking curative, consolidation, or palliative systemic/local therapy
• Stage I–II NSCLC patients medically fit for anatomic pulmonary resection (lobectomy, segmentectomy) or SBRT — assessed by pulmonary function testing (FEV1 >40% predicted post-resection, DLCO >40%)
• Stage III NSCLC patients eligible for concurrent chemoradiotherapy (PS ECOG 0–1, adequate cardiopulmonary reserve)
• Stage IV NSCLC patients with actionable driver mutations (EGFR, ALK, ROS1, KRAS G12C, MET, RET, BRAF, NTRK) suitable for first-line oral targeted therapy
• Stage IV NSCLC patients with high PD-L1 expression (TPS ≥50%) eligible for pembrolizumab monotherapy or combination chemoimmunotherapy
• Limited-stage SCLC patients (PS ECOG 0–2) eligible for concurrent cisplatin-etoposide + thoracic radiotherapy ± prophylactic cranial irradiation (PCI)
• Extensive-stage SCLC patients eligible for platinum-etoposide + atezolizumab or durvalumab
• Patients seeking second opinion on biopsy results, molecular profiling interpretation, or treatment planning from internationally trained oncologists
• Patients requiring minimally invasive VATS or robotic-assisted thoracic surgery (RATS) at centres where this is unavailable locally
• REQUIRED DIAGNOSTICS (Pre-Arrival or On Arrival):
• CT Chest with contrast (thin-slice, ≤1.5 mm reconstruction preferred)
• PET-CT (18F-FDG) for staging evaluation and treatment response assessment
• Brain MRI with gadolinium (mandatory for Stage III–IV and all SCLC)
• Bronchoscopy with BAL, TBLB, or EBUS-TBNA (for central lesions and mediastinal staging)
• CT-guided percutaneous needle biopsy (for peripheral lesions)
• Liquid biopsy / circulating tumour DNA (ctDNA) — if tissue insufficient for NGS
• Comprehensive NGS panel (tumour tissue and/or liquid biopsy) — EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK, PD-L1 IHC
• Pulmonary Function Tests (PFTs): spirometry, diffusing capacity (DLCO), 6-minute walk test
• Cardiac evaluation: ECG, 2D Echocardiogram (ECHO) — mandatory pre-surgery and pre-cisplatin chemotherapy
• Complete blood count, comprehensive metabolic panel, LFTs, RFTs, coagulation profile
• Bone scan or sodium fluoride PET (if bone metastasis clinically suspected)
• CONTRAINDICATIONS / RELATIVE EXCLUSIONS:
• ECOG Performance Status 3–4 for curative-intent surgery or aggressive chemoradiotherapy
• FEV1 or DLCO <30% predicted (high surgical mortality risk — refer to SBRT or non-surgical MDT discussion)
• Uncontrolled co-morbidities: severe COPD (GOLD Stage IV), decompensated heart failure (EF <30%), active myocardial infarction within 3 months
• Active autoimmune disease requiring systemic steroids (relative contraindication to immune checkpoint inhibitors)
• Pregnancy (systemic cytotoxic chemotherapy and thoracic radiotherapy contraindicated)
• Uncorrected severe pulmonary hypertension (mean PAP >35 mmHg) — surgical risk extreme
Procedure
SURGICAL APPROACHES:
1. Video-Assisted Thoracoscopic Surgery (VATS) Lobectomy / Segmentectomy — The global standard for Stage I–II NSCLC. Performed through 2–4 small ports (8–12 mm) without rib spreading. Offers equivalent oncological outcomes to open thoracotomy with significantly reduced morbidity, shorter hospital stay (5–7 days), and faster return to systemic therapy. Anatomic segmentectomy (sub-lobar resection) is now guideline-endorsed (JCOG0802 trial data) for tumours ≤2 cm with ground-glass opacity (GGO) predominance.
2. Robotic-Assisted Thoracic Surgery (RATS) — da Vinci Xi or SP platform. Provides 3D magnified vision, 7 degrees of wrist articulation, and tremor filtration — enabling complex hilar dissections, sleeve resections, and bronchoplastic procedures with higher precision. Preferred for centrally located tumours, post-induction cases, and patients requiring bronchial or vascular reconstruction. Available at GAF Healthcare's partner centres in India (Medanta, Apollo, Fortis) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai).
3. Open Thoracotomy (Posterolateral / Muscle-Sparing) — Reserved for pneumonectomy, complex chest wall resections (Stage IIIA with chest wall invasion), or cases anatomically unsuitable for minimally invasive approaches. Pneumonectomy carries a 30-day mortality of 5–8% and requires careful patient selection using the Thoracoscore and Brunelli risk models.
4. VATS Pleurodesis / Pleurectomy — For malignant pleural effusion palliation or mesothelioma debulking.
RADIATION THERAPY:
5. Stereotactic Body Radiotherapy (SBRT) / SABR — The definitive non-surgical treatment for medically inoperable Stage I–II NSCLC. Delivers ablative doses (48–60 Gy in 3–5 fractions) with sub-millimetre precision using real-time tumour tracking (Varian TrueBeam STx, Elekta Unity MR-Linac). Achieves local control rates of 85–95% at 3 years, comparable to surgery in retrospective pooled analyses.
6. Intensity-Modulated Radiation Therapy (IMRT) / Volumetric Modulated Arc Therapy (VMAT) — For concurrent chemoradiotherapy in Stage III NSCLC. Delivered with 4D-CT motion management and image-guided radiotherapy (IGRT) to spare heart, oesophagus, and contralateral lung (V20 <30%).
7. Proton Beam Therapy (PBT) — Available at select GAF Healthcare partner centres in India (Apollo Proton Cancer Centre, Chennai; HCG Panda, Cuttack). Exploits the Bragg peak to eliminate exit dose, particularly advantageous for re-irradiation, centrally located tumours abutting the oesophagus/heart, and paediatric cases.
SYSTEMIC THERAPY — TARGETED AGENTS:
8. EGFR-Mutant NSCLC: Osimertinib (Tagrisso, 3rd-generation EGFR TKI) — first-line standard per FLAURA2 trial, penetrates blood-brain barrier, PFS 25.5 months. Erlotinib, gefitinib, afatinib for exon 19/21 mutations where osimertinib is unavailable. Amivantamab + lazertinib for EGFR exon 20 insertion.
9. ALK-Rearranged NSCLC: Alectinib (Alecensa) or brigatinib first-line; lorlatinib for acquired resistance or brain-predominant disease.
10. ROS1-Rearranged NSCLC: Entrectinib or crizotinib; lorlatinib for resistance.
11. KRAS G12C-Mutant NSCLC: Sotorasib (Lumakras) or adagrasib (Krazati) — first approved KRAS inhibitors.
12. MET Exon 14 Skipping: Tepotinib (Tepmetko) or capmatinib (Tabrecta).
13. RET Fusion-Positive: Selpercatinib (Retevmo) or pralsetinib (Gavreto).
14. BRAF V600E: Dabrafenib + trametinib combination.
15. NTRK Fusion: Larotrectinib (Vitrakvi) or entrectinib.
SYSTEMIC THERAPY — IMMUNOTHERAPY:
16. Pembrolizumab (Keytruda) monotherapy — first-line for PD-L1 TPS ≥50% NSCLC (KEYNOTE-024). 17. Pembrolizumab + carboplatin/pemetrexed — first-line for non-squamous NSCLC regardless of PD-L1 (KEYNOTE-189). 18. Nivolumab + ipilimumab ± chemotherapy — first-line for NSCLC (CheckMate-9LA/227). 19. Durvalumab — consolidation after concurrent chemoradiotherapy for Stage III NSCLC (PACIFIC regimen, OS benefit sustained at 5 years). 20. Atezolizumab or durvalumab — added to platinum-etoposide for ES-SCLC.
CHEMOTHERAPY REGIMENS: 21. NSCLC (non-squamous): Cisplatin/carboplatin + pemetrexed ± bevacizumab. 22. NSCLC (squamous): Cisplatin/carboplatin + gemcitabine or paclitaxel. 23. SCLC: Cisplatin/carboplatin + etoposide (4–6 cycles). 24. Neoadjuvant/Induction: Nivolumab + platinum-doublet × 3 cycles pre-surgery (CheckMate-816 data — pCR rate 24% vs 2% chemotherapy alone).
INTERVENTIONAL / BRONCHOSCOPIC OPTIONS: 25. Endobronchial Ultrasound (EBUS-TBNA) — diagnostic and staging. 26. Bronchoscopic thermal ablation (Cryotherapy, APC, PDT) — for endobronchial tumour palliation. 27. Electromagnetic navigational bronchoscopy (ENB) — for peripheral lesion biopsy. 28. CT-guided microwave or radiofrequency ablation (RFA/MWA) — for small peripheral NSCLC in patients unfit for surgery or SBRT.
Cost of Lung Cancer Treatment: India vs. UAE
The cost of lung cancer treatment varies significantly by modality (surgery vs radiation vs systemic therapy), stage, duration of treatment, and hospital tier. India offers the same internationally trained specialists, NGS-guided precision oncology, and robotic surgical platforms as Western centres — at 50–65% lower cost than the UAE and 70–80% lower than the United States or UK. The UAE, particularly Dubai and Abu Dhabi, offers premium private hospital environments, Arabic-language care, visa-free or visa-on-arrival access for most GCC and African nationals, and proximity for patients from the Middle East and East Africa. Both destinations maintain JCI accreditation. The cost ranges below represent full treatment episode estimates per modality and do not include accommodation or international airfare.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $4,000 – $35,000 | ~57% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $10,000 – $80,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL PLANNING (2–4 Weeks Before Travel):
• Patient submits existing medical records (CT, PET-CT, biopsy reports, NGS results, PFT reports) to GAF Healthcare's oncology case management team via secure portal.
• GAF's medical team conducts a preliminary case review with the partner hospital's thoracic MDT and issues a written Treatment Plan Summary and Cost Estimate within 48–72 hours.
• GAF Healthcare initiates Indian e-Medical Visa application (or UAE entry visa process) — turnaround 3–5 business days for India e-Medical Visa.
• Pre-travel fitness assessment: patients on anticoagulants (for PE/DVT) are counselled on bridging protocols; patients on oral targeted therapy continue medication during transit.
• Accommodation for patient and one attendant arranged near hospital (service apartment or partner hotel).
PHASE 2 — ARRIVAL & PRE-TREATMENT WORKUP (Days 1–5):
• Day 1: Airport transfer by GAF Healthcare coordinator; hotel/hospital check-in; orientation meeting with dedicated bilingual case manager.
• Days 2–3: Repeat or supplementary diagnostics as required by MDT: CT chest (if >4 weeks old), brain MRI, ECHO, PFTs, blood panels, anaesthesia fitness assessment (ASA physical status, Revised Cardiac Risk Index — RCRI scoring).
• Day 4: Multidisciplinary Tumour Board meeting — patient may attend with interpreter if desired. Treatment intent (curative vs palliative), modality, and sequence finalised and documented.
• Day 5: Pre-admission counselling, informed consent, anaesthesia pre-op evaluation; bowel/pulmonary pre-habilitation instructions issued.
PHASE 3A — SURGICAL PATHWAY (Hospital Days 1–7 for VATS/Robotic; Days 1–14 for Open/Pneumonectomy):
• Day 1 (Surgery Day): General anaesthesia with double-lumen endotracheal tube (one-lung ventilation); intraoperative bronchoscopy to confirm endobronchial anatomy; VATS/RATS or open thoracotomy performed; intraoperative frozen section of bronchial margin and mediastinal nodes; chest drain placed.
• Days 2–3: ICU monitoring; epidural or paravertebral block analgesia; early ambulation protocol initiated Day 1 post-op; chest physiotherapy commenced; DVT prophylaxis (LMWH).
• Days 4–5: Chest drain removed when air leak resolved and drainage <200 mL/24h; chest X-ray confirms lung re-expansion; transition to oral analgesia.
• Days 5–7 (VATS/Robotic discharge): Discharge with written wound care instructions, analgesic schedule, physiotherapy plan, and follow-up PFT and CT at 6 weeks.
• Days 10–14 (Open/Pneumonectomy discharge): Extended physiotherapy, respiratory incentive spirometry, 6-minute walk test at discharge.
PHASE 3B — RADIATION THERAPY PATHWAY (SBRT: 1–2 Weeks; Concurrent CRT: 6–7 Weeks):
• Simulation CT with 4D motion capture; contouring review by radiation oncologist; physics plan optimisation and peer review (≥2 physicians).
• SBRT: 3–5 treatment fractions over 1–2 weeks (typically Monday/Wednesday/Friday schedule); patient ambulatory throughout; no hospitalisation required.
• Concurrent CRT (Stage III): 6–7 weeks of daily radiotherapy + weekly or 3-weekly cisplatin-based chemotherapy; monitoring CBC weekly, oesophagitis grading (CTCAE v5.0), and pulmonary toxicity assessment.
PHASE 3C — SYSTEMIC THERAPY INITIATION (Targeted/Immunotherapy/Chemotherapy):
• Cycle 1 administered under direct supervision at partner hospital with pre-medication protocol, pharmacist counselling, and toxicity monitoring.
• Subsequent cycles may be administered at patient's home country with GAF-provided treatment summary, dose schedule, and partner oncologist contact for remote consultation.
• CT or PET-CT response assessment at 6–8 weeks (RECIST 1.1 criteria).
PHASE 4 — RECOVERY & FIT-TO-FLY CLEARANCE:
• Post-VATS/Robotic resection: Cleared for international flight at 3 weeks, contingent on chest X-ray confirming no pneumothorax, adequate pain control, and absence of DVT on clinical assessment. LMWH prophylaxis prescribed for flight.
• Post-open thoracotomy/pneumonectomy: Cleared at 5–6 weeks after confirmed wound healing, stable spirometry, and cardiologist clearance.
• Post-SBRT: Cleared at 2–3 weeks after treatment completion.
• Post-chemotherapy Cycle 1: Cleared after nadir CBC recovery (typically Day 14–21) with WBC >3.0 × 10⁹/L and platelets >100 × 10⁹/L.
• All patients receive: GAF Healthcare discharge dossier (operative report, pathology with TNM stage, NGS results, imaging CDs, treatment summary in English + requested local language), 30-day remote follow-up WhatsApp/video consultation with treating oncologist.
Risks & Considerations
Lung cancer treatment carries procedure- and modality-specific risks that patients must understand prior to consent. For surgical resection (VATS/Robotic Lobectomy), risks include prolonged air leak (>5 days, occurring in 8–15% of cases), atrial fibrillation (15–20% post-lobectomy, most self-limiting), pneumonia (3–5%), bronchopleural fistula (<1% but potentially life-threatening), and in-hospital mortality of approximately 1–2% for lobectomy and 5–8% for pneumonectomy. Cardiopulmonary reserve reduction post-pneumonectomy is permanent; patients must be counselled on expected FEV1 decline using the ppoFEV1 formula. For SBRT, radiation pneumonitis occurs in 5–10% of patients (Grade ≥2), typically presenting 4–12 weeks post-treatment; chest wall pain and rib fracture are reported in 5–10% for peripheral tumours. For concurrent chemoradiotherapy (Stage III), oesophagitis (Grade 3 in 10–20%), radiation pneumonitis (Grade 3 in 7–15%), and cisplatin-related nephrotoxicity and ototoxicity are important toxicities. For immune checkpoint inhibitors (pembrolizumab, nivolumab, durvalumab), immune-related adverse events (irAEs) include pneumonitis (3–5% Grade 3+), hepatitis, colitis, endocrinopathies (thyroiditis, adrenal insufficiency), and rare but severe myocarditis (<1%, mortality ~25% if missed). Patients must carry an irAE alert card. For EGFR TKIs (osimertinib), interstitial lung disease (ILD/pneumonitis) occurs in 3–4% and requires prompt drug cessation. KRAS G12C inhibitors (sotorasib, adagrasib) carry risk of hepatotoxicity (Grade 3 ALT elevation in 6–8%) and ILD. All patients on systemic therapy are at elevated venous thromboembolism (VTE) risk; Khorana Score should be calculated and DOAC prophylaxis considered. Long-haul air travel post-thoracic surgery significantly elevates DVT/PE risk — all surgical patients must receive LMWH for the return flight and compression stockings. GAF Healthcare's partner centres conduct structured complication surveillance and provide 24/7 emergency contact protocols for travelling patients.
Top Hospitals for Lung Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Lung Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Balasubramoniam K R
MCh (CVTS), MS (General Surgery), MBBS
Thoracic & Lung Transplant Surgeon
Yashoda Hospitals, Hyderabad, India
18+ Yearsof experience
Dr. Balasubramoniam K R is a Consultant Robotic, Minimally Invasive Thoracic and Lung Transplant Surgeon with over 18 years of expertise in cardiothoracic and vascular surgery. He holds an MCh in Cardiovascular and Thoracic Surgery from the prestigious Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, and is currently practicing at Yashoda Hospitals in Hyderabad, one of India's leading multi-specialty healthcare… Read more
Dr. Kamran Ali
MBBS, DNB (Surgery), FACS (Fellow of American College of Surgeons), Fellowship in Thoracic Surgery, ASCVTS Fellowship, Fellowship in Lung Transplant
Thoracic & Lung Transplant Surgeon
Max Super Speciality Hospital, Saket, New Delhi, India
15+ Yearsof experience
Dr. Kamran Ali is a Principal Consultant in Thoracic Surgery at Max Super Speciality Hospital, Saket, New Delhi, with over 15 years of clinical experience in advanced thoracic and lung transplant surgery. He holds an MBBS from Jawaharlal Nehru Medical College, AMU Aligarh, and is a Fellow of the American College of Surgeons (FACS). His international training includes a prestigious Fellowship in Lung Transplantation from the Medical University of Vienna,… Read more
Dr. Manjunath Bale
MCh, MS (General Surgery), MBBS, MIS Fellowship, ATLS
Thoracic Oncosurgeon & Robotic Lung Surgeon
Yashoda Hospitals, Hyderabad, India
17+ Yearsof experience
Dr. Manjunath Bale is a Consultant Robotic and Minimally Invasive Thoracic Surgeon and Lung Transplant Specialist at Yashoda Hospitals, Hyderabad. With over 17 years of clinical experience, he has established himself as a pioneer in advanced thoracic surgical techniques. He completed his MCh and MS in General Surgery from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized fellowships in minimally invasive… Read more
Dr. Belal Bin Asaf
MBBS, MS (Surgery), Fellowship in Thoracic Surgery, Certification as Robotic Console Surgeon, Observing Fellowship in VATS Lobectomy, Training in Minimally Invasive Esophagectomy
Thoracic Surgical Oncologist
Medanta — The Medicity, Gurugram, India
20+ Yearsof experience
Dr. Belal Bin Asaf is a distinguished Thoracic Surgical Oncologist and Director of Surgical Oncology at Medanta — The Medicity in Gurugram. With over 20 years of clinical experience, he has established himself as a pioneering leader in minimally invasive thoracic surgical oncology across India. His credentials include MBBS, MS in Surgery, Fellowship in Thoracic Surgery, and specialized certification as a Robotic Console Surgeon, combined with focused… Read more
Dr. Harsh Vardhan Puri
MBBS, DNB, DNB Superspeciality
Thoracic Surgeon & Surgical Oncologist
Medanta - The Medicity, Delhi NCR, India
12+ Yearsof experience
Dr. Harsh Vardhan Puri is a Senior Consultant in Surgical Oncology and Thoracic Surgery at Medanta — The Medicity in Delhi NCR, with over 12 years of clinical experience. He holds the distinction of being India's first board-certified Thoracic Surgeon and has been honored with the Presidents Gold Medal in Thoracic Surgery from the National Board of Examinations — a recognition that underscores his exceptional expertise and leadership in the field. Dr.… Read more
Frequently Asked Questions — Lung Cancer Treatment
The cost of lung cancer treatment varies by modality and stage. In India, a VATS lobectomy (surgery alone, including hospital stay, anaesthesia, and standard medications) typically costs USD 6,000–12,000. A course of SBRT runs USD 4,000–8,000. A complete concurrent chemoradiotherapy programme (6–7 weeks) costs USD 8,000–18,000. First-line systemic therapy initiation (targeted agents or immunotherapy, per cycle) costs USD 1,500–5,000 per cycle depending on the drug. In the UAE (Dubai/Abu Dhabi), equivalent procedures cost approximately 60–100% more: VATS lobectomy USD 18,000–35,000; SBRT USD 15,000–28,000; concurrent CRT USD 22,000–55,000; and systemic therapy initiation USD 5,000–15,000 per cycle. Both destinations provide JCI-accredited hospitals, internationally trained thoracic oncologists, NGS-guided molecular profiling, and robotic surgical platforms. India offers the lowest cost globally for equivalent clinical quality, while the UAE offers premium private hospital environments and superior geographic convenience for patients from the GCC, East Africa, and the broader Arab world. GAF Healthcare provides a personalised itemised cost estimate within 48 hours of receiving your medical records, with no obligation to proceed.
Fit-to-fly timelines are modality-specific and are determined by your thoracic surgeon or oncologist at the treating centre. After VATS or robotic-assisted lobectomy or segmentectomy, most patients are cleared for international flight at 3 weeks post-surgery, provided chest X-ray confirms no residual pneumothorax, pain is controlled on oral analgesia, and there are no signs of DVT on clinical assessment. Long-haul flights carry an elevated risk of deep vein thrombosis (DVT) and pulmonary embolism after thoracic surgery; all surgical patients receive a prescription for low molecular weight heparin (LMWH) and compression stockings for the return journey. After open thoracotomy or pneumonectomy, the fit-to-fly timeline is extended to 5–6 weeks, contingent on wound healing, stable spirometry, and cardiologist clearance. After SBRT, patients are typically cleared to fly 2–3 weeks after the final fraction once acute radiation reactions have settled. After the first cycle of chemotherapy, patients must wait until bone marrow nadir recovery — usually Day 14–21 — with white blood cell count above 3.0 × 10⁹/L and platelets above 100 × 10⁹/L before long-haul travel. Patients on oral targeted therapy (e.g., osimertinib, alectinib) may travel once tolerating the medication without significant side effects, typically 2–3 weeks after initiation. GAF Healthcare issues a formal fit-to-fly certificate from the treating physician, which is accepted by airlines for boarding with medical documentation.
Success rates in lung cancer are stage- and modality-dependent and are best understood by specific disease scenario. For Stage I NSCLC treated with curative-intent VATS or robotic lobectomy, the 5-year overall survival rate is 70–90% (Stage IA3: 77–90%; Stage IB: 68–75% per IASLC data). SBRT for medically inoperable Stage I NSCLC achieves local control rates of 85–95% at 3 years, with 5-year overall survival of 40–60% (reflecting co-morbidities rather than oncological failure). For Stage II NSCLC with surgery ± adjuvant chemotherapy or osimertinib (ADAURA trial for EGFR-mutant disease, 88% DFS at 4 years), 5-year survival is 53–65%. For Stage III NSCLC managed with concurrent chemoradiotherapy plus durvalumab consolidation (PACIFIC regimen), median overall survival exceeds 47 months with a 5-year OS rate of approximately 42%. For Stage IV EGFR-mutant NSCLC treated with osimertinib, median progression-free survival is 18–25 months and median overall survival exceeds 38 months per the FLAURA data. For Stage IV ALK-rearranged NSCLC on alectinib, median PFS is 34 months. For high PD-L1 expressors (TPS ≥50%) on pembrolizumab monotherapy, 5-year OS rates of 31% have been reported in the KEYNOTE-024 trial — a remarkable benchmark for Stage IV disease. SCLC limited-stage achieves 5-year OS of 20–35% with concurrent chemoradiotherapy; extensive-stage SCLC median OS is 12–13 months with modern chemoimmunotherapy. GAF Healthcare's partner centres treat high volumes of thoracic oncology cases and submit outcomes data to international tumour registries, ensuring transparency and accountability.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical coordination that begins the moment a patient enquires and continues through post-departure remote follow-up.
VISA & DOCUMENTATION — INDIA:
• GAF facilitates the Indian e-Medical Visa application, which is available to nationals of most countries and processed online through the Indian Government portal in 3–5 business days.
• The e-Medical Visa permits an initial 60-day stay with two extensions (up to 180 days total) — sufficient for multi-cycle chemotherapy or concurrent chemoradiotherapy courses.
• GAF provides the mandatory visa support letter on partner hospital letterhead, treatment cost estimate, and patient identity documents checklist.
• Patients are advised to apply at least 10 business days before travel; GAF's visa assistance team monitors application status and responds to consulate queries.
VISA & ENTRY — UAE:
• GCC nationals do not require a visa for Dubai or Abu Dhabi.
• Nationals of 50+ countries (including the EU, UK, US, Canada, Australia, and most South and Southeast Asian countries) receive a free 30- or 90-day visa on arrival.
• For nationalities requiring advance UAE visa, GAF facilitates a medical treatment visa application through the General Directorate of Residency and Foreigners Affairs (GDRFA) — processed in 5–7 business days.
• Extended treatment stays (>90 days) can be facilitated through a formal patient visa extension with the partner hospital's international patient services department.
AIRPORT TRANSFERS:
• Private air-conditioned vehicle pickup from arrival airport for patient and up to two attendants; wheelchair-accessible vehicles available on request.
• In-country intercity transfers (e.g., Mumbai to Chennai for Proton Therapy) coordinated by GAF.
DEDICATED CASE MANAGER & TRANSLATION:
• Every GAF Healthcare patient is assigned a named, bilingual case manager fluent in the patient's language (Arabic, French, Russian, Swahili, Hindi, and 20+ other languages available).
• On-site medical interpreters accompany patients to consultations, procedure consent discussions, and discharge briefings.
• All medical documents (operative reports, pathology, NGS reports) translated into the patient's preferred language as part of the discharge dossier.
ACCOMMODATION:
• Service apartments and partner hotels within 1–3 km of the treating hospital reserved for the patient and one or two accompanying attendants — priced from USD 30/night (India, budget) to USD 250/night (UAE, premium).
• For prolonged treatment stays (chemoradiotherapy, 6–7 weeks), discounted monthly apartment rates are negotiated by GAF on the patient's behalf.
• Meals, housekeeping, and local SIM card provisioning included in premium accommodation packages.
CONTINUITY OF CARE POST-DEPARTURE:
• 30-day remote consultation access to the treating oncologist via GAF's secure teleconsultation platform.
• Digital prescription and lab requisition service for cycle 2+ chemotherapy to be administered in the home country.
• Emergency medical repatriation coordination in partnership with international medical assistance providers.
Patients Also Explore
Other treatments commonly sought by patients considering Lung Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology